obesity

View All

emerging-therapies-for-obesity-treatment
Obesity Treatment: Which Pipeline Therapy Will Revolutionize the Therapeutics Segment?

Obesity is the second most common cause of preventable death, associated with the risk of developing inflammatory components, directly and indirectly, related to cardiovascular disease, diabetes mellitus, respiratory problems, psychological issues, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. ...

Find More

obesity-treatment-landscape
Obesity: A Worldwide Pandemic with Advancing Management Options

Obesity is a chronic health condition that leads to abnormal or excessive fat accumulation or adipose tissue in the body that presents a health risk. It is an imbalance between calories ingested and calories burned. The factors responsible for the causes of obesity include heredity, a sedentary lifestyle, excessive...

Find More

Mobile Apps for Chronic Diseases Management
Assessing the Growing Role & the Demand of Apps in Managing the Chronic Diseases

Over the past few years, the prevalence of the chronic disease has grown significantly. The rising prevalence is leading to a severe social and economical burden on the individuals and their families. Chronic diseases are long-lasting conditions with endless side effects associated with them. Despite the rise in mo...

Find More

bispecific-antibodies
Rise In Bispecific Antibodies Utilization As Antibody Therapeutics

Bispecific Antibodies (BsAbs) are antibodies that contain two different antigens or have two different epitopes on the same antigen. It is observed for Bispecific Antibodies in clinical trials that the therapeutic effects of these are considerably higher than those of monoclonal antibodies (MoAbs). There are a vast...

Find More

weight-loss-obesity-market
An Insight Into the Weight Loss and Obesity Market

Obesity is one of the significant global health challenges, having a severe socio-economic impact.  It is basically an imbalance in calories consumed versus calories expended. Over the past two to three decades, it has grown to be a global epidemic and impacting people across age and geographic regions, which ...

Find More

obesity-causes-diagnosis-risk-factors-epidemiology-therapies-pipeline-treatment-therapeutics-market
The Obesity Pandemic: What can we do about it?

Obesity today is a global crisis; the number of cases is on a continuous rise. As per the WHO,  “during the years 1975 to 2016, the prevalence of overweight or obese children and adolescents aged 5–19 years increased more than four-fold from 4% to 18% globally”. In 2016, more than 1.9 billion adults, 18 years ...

Find More

Leading-Causes-of-Death-Worldwide
What are the Top Five Leading Causes of Deaths in the World?

The global healthcare system over the past few decades has transformed exponentially. Today we are living twice as long as our ancestors have lived before. Infrastructure development, technological advancements (such as accurate diagnosis and lesser medical errors), public-private partnerships in healthcare, availa...

Find More

Healthcare scenario in MENA region
Booming Healthcare sector in MENA: Lucrative opportunity for Global pharma players

The Middle-East and North-Africa region (MENA), which encompasses some of the world’s wealthiest economies, extends unparalleled opportunities to multinational corporations with expertise in medical devices. There is a conspicuous disparity in the economic prowess across the countries, but most of them have shown r...

Find More

Digital therapeutics
Potential of Digital therapeutics and increasing CVDs

The 21st century has been a remarkable century for humankind, as a lot of innovation, research and development has taken place in the field of healthcare, due to which we have been able to increase the overall lifespan of the human beings.  However, the central question is, are we able to increase the healt...

Find More

astellas
Commercial

NICE Rejects Gilead Sciences’ Yescarta on Cost Concerns The United Kingdom’s government-funded health service isn’t being so nice to Gilead Sciences’ CAR-T blood cancer treatment Yescarta. The country’s National Institute for Health and Care Excellence (NICE) said the therapy is too expensive for th...

Find More